Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.
about
Interventions for fatigue and weight loss in adults with advanced progressive illnessScreening for chronic comorbid diseases in people with HIV: the need for a strategic approachA cross-sectional randomised study of fracture risk in people with HIV infection in the probono 1 studyHIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study.Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in CambodiaRisk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population.Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospitalUrinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy.Prevalence of traditional cardiovascular risk factors and evaluation of cardiovascular risk using three risk equations in nigerians living with human immunodeficiency virus.Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis.Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis.WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.Sex Differences in Tobacco Use Among Persons Living With HIV/AIDS: A Systematic Review and Meta-Analysis.Assessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical Systems.Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy.Differences by HIV serostatus in coronary artery disease severity and likelihood of percutaneous coronary intervention following stress testing.Type 2 diabetes prevalence and its risk factors in HIV: A cross-sectional study.Changes in cardiovascular risk and clinical outcomes in a HIV/AIDS cohort study over a 1-year period at a specialized clinic in Mexico
P2860
Q24203914-1ABAF1EE-9CAF-42AC-80E3-1450D90F5ECDQ26866452-C4179329-A59C-4B5A-9102-3EB34D6D786FQ28534700-7D8A3D79-FE30-4ADE-9885-AC59EB6BE67BQ35035055-354E05A4-9CFE-48E7-AFCF-C43718895A2FQ35644326-A7CC45F3-CBA5-430F-9046-934CD0432152Q36118338-0FC9531D-684C-4DDC-AADC-CDCBCC25D39BQ36497046-2C4A146A-354D-4084-98CE-66D17BFA4000Q36865445-0B77929A-5307-4816-BA4C-322AE94744C6Q37049808-F7843080-1A10-460F-9BFB-D65C21488207Q37424016-F5CDA0A0-93BA-4681-90D4-5D85F24BF942Q37641013-CF1E2694-FE03-4852-8268-E05111053642Q37993138-C722A42B-EEAB-4F9F-9A16-A315E5FE6BE1Q38601769-B5D95228-02A3-467D-AB55-E2793C44687CQ38733702-2C49BFDF-CFF3-453A-852D-34C8683B07D2Q39046688-25F376A9-2844-40D1-9110-764C74D718F7Q39077480-6B7142AC-D40C-449A-B32F-4C9ACF0CCF11Q39172811-45C8CE62-933F-46FD-9DE6-94A67F352CF0Q39293076-AA0CE748-9116-4A89-855C-31820F6C2A17Q54257862-82D4F826-A4A3-4942-BAD6-51E381F3D87BQ57070083-7A6D010C-C2C2-40AC-A5CE-70C7184BB27B
P2860
Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@ast
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@en
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@nl
type
label
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@ast
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@en
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@nl
prefLabel
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@ast
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@en
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@nl
P2093
P2860
P1476
Cardiovascular risk evaluation ...... anagement: the CREATE 1 study.
@en
P2093
A S Wierzbicki
B S Peters
E Skopelitis
G Panayiotakopoulos
P2860
P304
P356
10.1111/J.1742-1241.2010.02424.X
P577
2010-08-01T00:00:00Z